International Scoring System for Evaluating Prognosis in Myelodysplastic Syndromes

International System for Human Cytogenetic Nomenclature

National Cancer Institute (2020) · Definitions · doi:10.32388/78qroa · Cited by 6,831

Proposals for the classification of the myelodysplastic syndromes

Bennett, J. M., Catovsky, D., Daniel, M., Flandrin, G., Galton, D. A. G., Gralnick, H. R., & Sultan, C. (1982) · British Journal of Haematology · doi:10.1111/j.1365-2141.1982.tb08475.x · Cited by 3,619

Myelodysplastic syndromes: a scoring system with prognostic significance

Mufti, G. J., Stevens, J. R., Oscier, D. G., Hamblin, T. J., & Machin, D. (1985) · British Journal of Haematology · doi:10.1111/j.1365-2141.1985.tb07329.x · Cited by 507

The chronic myeloid leukaemias: guidelines for distinguishing chronic granulocytic, atypical chronic myeloid, and chronic myelomonocytic leukaemia: Proposals by the French ‐ American ‐ British Cooperative Leukaemia Group

Bennett, J. M., Catovsky, D., Daniel, M., Flandrin, G., Galton, D. A. G., Gralnick, H. R., Sultan, C., & Cox, C. (1994) · British Journal of Haematology · doi:10.1111/j.1365-2141.1994.tb06734.x · Cited by 431

Two regression models and a scoring system for predicting survival and planning treatment in myelodysplastic syndromes: a multivariate analysis of prognostic factors in 370 patients

Sanz, G. F., Sanz, M. Á., Vallespı́, T., Cañizo, M., Torrabadella, M., Garcia, S., Irriguible, D., & Miguel, J. F. S. (1989) · Blood · doi:10.1182/blood.v74.1.395.395 · Cited by 406

The 5q− anomaly

BERGHE, H. V. D., Vermaelen, K., Mecucci, C., Barbieri, D., & Tricot, G. J. K. (1985) · Cancer Genetics and Cytogenetics · doi:10.1016/0165-4608(85)90016-0 · Cited by 322

Cytogenetic analysis has strong independent prognostic value in de novo myelodysplastic syndromes and can be incorporated in a new scoring system: a report on 408 cases.

Morel, P., Hebbar, M., Laï, J. L., Duhamel, A., Preudhomme, C., Wattel, E., Bauters, F., & Fenaux, P. (1993) · PubMed · Cited by 300

Primary myelodysplastic syndromes: analysis of prognostic factors in 235 patients and proposals for an improved scoring system.

Aul, C., Gattermann, N., Heyll, A., Germing, U., Derigs, G., & Schneider, W. (1992) · PubMed · Cited by 265

Prognostic implications of morphology and karyotype in primary myelodysplastic syndromes

Rh, J., Cornbleet, M., Vardiman, J., Larson, R. A., Beau, M. M. L., & Rowley, J. (1986) · Blood · doi:10.1182/blood.v67.6.1765.1765 · Cited by 246

Refined chromosome study helps define prognostic subgroups in most patients with primary myelodysplastic syndrome and acute myelogenous leukaemia

Yunis, J. J., Lobell, M., Arnesen, M. A., Oken, M. M., Mayer, M. G., Rydell, R. E., & Brunning, R. D. (1988) · British Journal of Haematology · doi:10.1111/j.1365-2141.1988.tb06188.x · Cited by 232

A scoring system based on the expression of six surface molecules allows the identification of three prognostic risk groups in B‐cell chronic lymphocytic leukemia

Zucchetto, A., Bomben, R., Bo, M. D., Sonego, P., Nanni, P., Rupolo, M., Bulian, P., Maso, L. D., Poeta, G. D., Principe, M. I. D., et al. (2005) · Journal of Cellular Physiology · doi:10.1002/jcp.20570 · Cited by 57

Causality of myelodysplasia and acute myeloid leukemia and their genetic abnormalities

Pedersen-Bjergaard, J., Christiansen, D., Andersen, M., & Skovby, F. (2002) · Leukemia · doi:10.1038/sj.leu.2402764 · Cited by 57

Improvement of iron-mediated oxidative DNA damage in patients with transfusion-dependent myelodysplastic syndrome by treatment with deferasirox

Kikuchi, S., Kobune, M., Iyama, S., Sato, T., Murase, K., Kawano, Y., Takada, K., Ono, K., Kaneko, Y., Miyanishi, K., et al. (2012) · Free Radical Biology and Medicine · doi:10.1016/j.freeradbiomed.2012.06.006 · Cited by 56

Azacitidine in adult patients with acute myeloid leukemia

Schuh, A. C., Döhner, H., Pleyer, L., Seymour, J. F., Fenaux, P., & Dombret, H. (2017) · Critical Reviews in Oncology/Hematology · doi:10.1016/j.critrevonc.2017.05.010 · Cited by 57

Therapy for lower-risk MDS

Carraway, H. E., & Saygin, C. (2020) · Hematology · doi:10.1182/hematology.2020000127 · Cited by 56

Hematopoietic Cell Transplantation in the Management of Myelodysplastic Syndrome: An Evidence-Based Review from the American Society for Transplantation and Cellular Therapy Committee on Practice Guidelines

DeFilipp, Z. M., Ciurea, S. O., Cutler, C. S., Robin, M., Warlick, E. D., Nakamura, R., Brunner, A. M., Dholaria, B., Walker, A. R., Kröger, N. M., et al. (2022) · Transplantation and Cellular Therapy · doi:10.1016/j.jtct.2022.11.014 · Cited by 57

Reduced-intensity hematopoietic cell transplantation in older patients with AML/MDS: umbilical cord blood is a feasible option for patients without HLA-matched sibling donors

Majhail, N. S., Brunstein, C. G., Shanley, R., Sandhu, K., McClune, B. L., Oran, B., Warlick, E. D., Wagner, J. E., & Weisdorf, D. J. (2011) · Bone Marrow Transplantation · doi:10.1038/bmt.2011.114 · Cited by 56

Treosulfan, Fludarabine, and 2-Gy Total Body Irradiation Followed by Allogeneic Hematopoietic Cell Transplantation in Patients with Myelodysplastic Syndrome and Acute Myeloid Leukemia

Gyurkocza, B., Gutman, J. A., Nemecek, E. R., Bar, M., Milano, F., Ramakrishnan, A., Scott, B. L., Fang, M., Wood, B. L., Pagel, J. M., et al. (2014) · Transplantation and Cellular Therapy · doi:10.1016/j.bbmt.2014.01.009 · Cited by 56

Implementation of standardized international karyotype scoring practices is needed to provide uniform and systematic evaluation for patients with myelodysplastic syndrome using IPSS criteria: An International Working Group on MDS Cytogenetics Study

Chun, K., Hagemeijer, A., Iqbal, M. A., & Slovak, M. L. (2009) · Leukemia Research · doi:10.1016/j.leukres.2009.07.006 · Cited by 56

Distribution of cytogenetic abnormalities in myelodysplastic syndromes, Philadelphia negative myeloproliferative neoplasms, and the overlap MDS/MPN category

Bacher, U., Schnittger, S., Kern, W., Weiss, T., Haferlach, T., & Haferlach, C. (2009) · Annals of Hematology · doi:10.1007/s00277-009-0745-3 · Cited by 55

Impact of the revised International Prognostic Scoring System, cytogenetics and monosomal karyotype on outcome after allogeneic stem cell transplantation for myelodysplastic syndromes and secondary acute myeloid leukemia evolving from myelodysplastic syndromes: a retrospective multicenter study of the European Society of Blood and Marrow Transplantation

Koenecke, C., Göhring, G., de Wreede, L. C., van Biezen, A., Scheid, C., Volin, L., Maertens, J., Finke, J., Schaap, N. P., Robin, M., et al. (2014) · Haematologica · doi:10.3324/haematol.2014.116715 · Cited by 56

Allogeneic stem cell transplantation for patients with refractory anaemia with matched related and unrelated donors: delay of the transplant is associated with inferior survival

de Witte, T., Brand, R., van Biezen, A., Mufti, G. J., Ruutu, T., Finke, J., Borne, P. A. V. D., Vı́tek, A., Delforge, M., Alessandrino, P. E., et al. (2009) · British Journal of Haematology · doi:10.1111/j.1365-2141.2009.07809.x · Cited by 56

Unique balanced chromosome abnormalities in treatment‐related myelodysplastic syndromes and acute myeloid leukemia: Report from an International Workshop†

Olney, H. J., Mitelman, F., Johansson, B., Mrózek, K., Berger, R., & Rowley, J. D. (2002) · Genes Chromosomes and Cancer · doi:10.1002/gcc.10045 · Cited by 56

Genetic Testing in the Myelodysplastic Syndromes: Molecular Insights Into Hematologic Diversity

Steensma, D. P., & List, A. F. (2005) · Mayo Clinic Proceedings · doi:10.4065/80.5.681 · Cited by 56

Clinical Management of Myelodysplastic Syndromes With Interstitial Deletion of Chromosome 5q

Nimer, S. D. (2006) · Journal of Clinical Oncology · doi:10.1200/jco.2005.03.6715 · Cited by 56

An assessment of erythroid response to epoetin α as a single agent versus in combination with granulocyte– or granulocyte‐macrophage–colony‐stimulating factor in myelodysplastic syndromes using a meta‐analysis approach

Mundle, S. D., Lefèbvre, P., Vekeman, F., Duh, M. S., Rastogi, R., & Moyo, V. M. (2009) · Cancer · doi:10.1002/cncr.24090 · Cited by 57

Concurrent Inflammatory Bowel Disease and Myelodysplastic Syndromes

Harewood, G. C., Loftus, E. V., Tefferi, A., Tremaine, W. J., & Sandborn, W. J. (1999) · Inflammatory Bowel Diseases · doi:10.1097/00054725-199905000-00005 · Cited by 56

Infliximab chimaeric anti-tumour necrosis factor alpha monoclonal antibody treatment for patients with myelodysplastic syndromes

Stasi, R., & Amadori, S. (2002) · British Journal of Haematology · doi:10.1046/j.0007-1048.2001.03279.x · Cited by 56

A patient-oriented approach to treatment of myelodysplastic syndromes.

Cazzola, M., Anderson, J. E., Ganser, A., & Hellström‐Lindberg, E. (1998) · PubMed · Cited by 56

Myelodysplastic Syndromes: Diagnosis and Staging

Malcovati, L., & Nimer, S. D. (2008) · Cancer Control · doi:10.1177/107327480801504s02 · Cited by 55

Prognostic Value of Isocitrate Dehydrogenase Mutations in Myelodysplastic Syndromes: A Retrospective Cohort Study and Meta-Analysis

Jin, J., Hu, C., Yu, M., Chen, F., Ye, L., Yin, X., Zhuang, Z., & Tong, H. (2014) · PLoS ONE · doi:10.1371/journal.pone.0100206 · Cited by 56

Safety and efficacy of thrombopoietin‐receptor agonists in myelodysplastic syndromes: a systematic review and meta‐analysis of randomized controlled trials

Prica, A. A., Sholzberg, M., & Buckstein, R. J. (2014) · British Journal of Haematology · doi:10.1111/bjh.13088 · Cited by 55

Combined treatment with lenalidomide and epoetin alfa in lower-risk patients with myelodysplastic syndrome

Komrokji, R. S., Lancet, J. E., Swern, A. S., Chen, N., Paleveda, J., Lush, R. M., Saba, H. I., & List, A. F. (2012) · Blood · doi:10.1182/blood-2012-03-415661 · Cited by 55

Managing myelodysplastic symptoms in elderly patients

Ria, R. (2009) · Clinical Interventions in Aging · doi:10.2147/cia.s5203 · Cited by 55

A Phase I Study of Oral ARRY-614, a p38 MAPK/Tie2 Dual Inhibitor, in Patients with Low or Intermediate-1 Risk Myelodysplastic Syndromes

Garcia‐Manero, G., Khoury, H. J., Jabbour, E. J., Lancet, J. E., Winski, S. L., Cable, L., Rush, S. A., Maloney, L., Hogeland, G., Ptaszynski, M., et al. (2014) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-14-1765 · Cited by 55

Myelodysplastic Syndromes

Scott, B. L., & Deeg, H. J. (2010) · Annual Review of Medicine · doi:10.1146/annurev.med.051308.132852 · Cited by 56

Hematopoietic Growth Factors in the Treatment of Acquired Bone Marrow Failure States

Marsh, J. C. W., Ganser, A., & Stadler, M. (2007) · Seminars in Hematology · doi:10.1053/j.seminhematol.2007.04.010 · Cited by 55

Adiponectin and resistin are associated with risk for myelodysplastic syndrome, independently from the insulin-like growth factor-I (IGF-I) system

Dalamaga, Μ., Καρμανιώλας, Κ., Nikolaidou, A., Chamberland, J. P., Hsi, A., Dionyssiou‐Asteriou, A., & Mantzoros, C. S. (2008) · European Journal of Cancer · doi:10.1016/j.ejca.2008.04.015 · Cited by 55

Cytogenetic analogy between myelodysplastic syndrome and acute myeloid leukemia of elderly patients

Rossi, G., Pelizzari, A. M., Bellotti, D., Tonelli, M., & Barlati, S. (2000) · Leukemia · doi:10.1038/sj.leu.2401711 · Cited by 55

Chemotherapy only compared to chemotherapy followed by transplantation in high risk myelodysplastic syndrome and secondary acute myeloid leukemia; two parallel studies adjusted for various prognostic factors

Oosterveld, M., Muus, P., Suciu, S., Koller, C. A., Verhoef, G. E. G., Labar, B., Wijermans, P., Aul, C., Fiere, D. M., Selleslag, D., et al. (2002) · Leukemia · doi:10.1038/sj.leu.2402591 · Cited by 55

Outcomes of alemtuzumab‐based reduced intensity conditioning stem cell transplantation using unrelated donors for myelodysplastic syndromes

Lim, Z. Y., Ho, A. Y. L., Ingram, W. A., Kenyon, M., Pearce, L., Czepulkowski, B. H., Devereux, S., Duarte, R. F., Pagliuca, A., & Mufti, G. J. (2006) · British Journal of Haematology · doi:10.1111/j.1365-2141.2006.06272.x · Cited by 55

Myelodysplastic syndromes with ring sideroblasts ( MDS‐RS ) and MDS /myeloproliferative neoplasm with RS and thrombocytosis ( MDS/MPN‐RS‐T ) – “ 2021 update on diagnosis, risk‐stratification, and management”

Patnaik, M. M., & Tefferi, A. (2021) · American Journal of Hematology · doi:10.1002/ajh.26090 · Cited by 57

Increased level of H-ferritin and its imbalance with L-ferritin, in bone marrow and liver of patients with adult onset Still's disease, developing macrophage activation syndrome, correlate with the severity of the disease

Ruscitti, P., Cipriani, P., Benedetto, P. D., Ciccia, F., Liakouli, V., Carubbi, F., Berardicurti, O., Rizzo, A. G., Triolo, G., & Giacomelli, R. (2015) · Autoimmunity Reviews · doi:10.1016/j.autrev.2015.01.004 · Cited by 54

Targeting Immune Dysregulation in Myelodysplastic Syndromes

Olnes, M. J. (2011) · JAMA · doi:10.1001/jama.2011.194 · Cited by 54

The bone marrow stroma in hematological neoplasms—a guilty bystander

Tripodo, C., Sangaletti, S., Piccaluga, P. P., Prakash, S., Franco, G. M., Borrello, I., Orazi, A., Colombo, M. P., & Pileri, S. A. (2011) · Nature Reviews Clinical Oncology · doi:10.1038/nrclinonc.2011.31 · Cited by 53

Myelodysplastic Syndromes, Version 2.2015

Greenberg, P. L., Stone, R. M., Bejar, R. L., Bennett, J. M., Bloomfield, C. D., Borate, U., de Castro, C. M., Deeg, H. J., Dezern, A. E., Fathi, A. T., et al. (2015) · Journal of the National Comprehensive Cancer Network · doi:10.6004/jnccn.2015.0038 · Cited by 56

Acquisition of cytogenetic abnormalities in patients with IPSS defined lower‐risk myelodysplastic syndrome is associated with poor prognosis and transformation to acute myelogenous leukemia

Jabbour, E. J., Takahashi, K., Wang, X., Cornelison, A. M., Abruzzo, L. V., Kadia, T. M., Borthakur, G. M., Estrov, Z. E., O'Brien, S. M., Mallo, M., et al. (2013) · American Journal of Hematology · doi:10.1002/ajh.23513 · Cited by 54

Down-regulation of Dicer1 promotes cellular senescence and decreases the differentiation and stem cell-supporting capacities of mesenchymal stromal cells in patients with myelodysplastic syndrome

Zhao, Y., Wu, D., Fei, C., Guo, J., Gu, S., Zhu, Y., Xu, F., Zhang, Z.-L., Wu, L., Li, X., et al. (2014) · Haematologica · doi:10.3324/haematol.2014.109769 · Cited by 55

Tumor genetic alterations and features of the immune microenvironment drive myelodysplastic syndrome escape and progression

Montes, P., Bernal, M., Campo, L. N., Ramírez, A. R. G., Jiménez, P., Garrido, P., Jurado, M., Garrido, F., Ruiz‐Cabello, F., & Hernandez, F. M. (2019) · Cancer Immunology Immunotherapy · doi:10.1007/s00262-019-02420-x · Cited by 54

Remicade as TNF Suppressor in Patients with Myelodysplastic Syndromes

Raza, A., Candoni, A., Khan, U. A., Lisak, L., Tahir, S. H., Silvestri, F., Billmeier, J., Alvi, M. I., Mumtaz, M. A., Gezer, S., et al. (2004) · Leukemia & lymphoma/Leukemia and lymphoma · doi:10.1080/10428190410001723322 · Cited by 54

Apoptosis in patients with myelodysplastic syndromes: differential involvement of marrow cells in ‘good’ versus ‘poor’ prognosis patients and correlation with apoptosis-related genes

Tsoplou, P., Kouraklis‐Symeonidis, A., Thanopoulou, E., Zikos, P., Orphanos, V., & Zoumbos, N. (1999) · Leukemia · doi:10.1038/sj.leu.2401538 · Cited by 54

Azacitidine

Issa, J. J., Kantarjian, H. M., & Kirkpatrick, P. (2005) · Nature Reviews Drug Discovery · doi:10.1038/nrd1726 · Cited by 55

Treatment of myelodysplastic syndromes with 5-azacytidine

Gryn, J. F., Zeigler, Z. R., Shadduck, R. K., LISTER, J. W., Raymond, J. M., Sbeitan, I., Srodes, C., Meisner, D. J., & Evans, C. D. (2002) · Leukemia Research · doi:10.1016/s0145-2126(02)00028-0 · Cited by 54

Targeting Hypomethylation of DNA to Achieve Cellular Differentiation in Myelodysplastic Syndromes (MDS)

Silverman, L. R. (2001) · The Oncologist · doi:10.1634/theoncologist.6-2004-8 · Cited by 54

The myelodysplastic syndromes flow cytometric score: a three-parameter prognostic flow cytometric scoring system

Alhan, C., Westers, T. M., Cremers, E. M. P., Cali, C., Lissenberg-Witte, B. I., Ossenkoppele, G. J., & van de Loosdrecht, A. A. (2015) · Leukemia · doi:10.1038/leu.2015.295 · Cited by 53

Prognostic impact of severe thrombocytopenia in low‐risk myelodysplastic syndrome

González‐Porras, J. R., Córdoba, I., Such, E., Nomdedeu, B., Vallespı́, T., Carbonell, F., Luño, E., Ardanaz, M., Ramos, F., Pedro, C., et al. (2011) · Cancer · doi:10.1002/cncr.26173 · Cited by 53

Diagnostic microRNAs in myelodysplastic syndrome

Erdoğan, B., Facey, C., Qualtieri, J. N., Tedesco, J., Rinker, E. B., Isett, R. B., Tobias, J. W., Baldwin, D. A., Thompson, J. E., Carroll, M. P., et al. (2011) · Experimental Hematology · doi:10.1016/j.exphem.2011.06.002 · Cited by 53

MDS prognostic scoring systems – Past, present, and future

Jonas, B. A., & Greenberg, P. L. (2014) · Best Practice & Research Clinical Haematology · doi:10.1016/j.beha.2014.11.001 · Cited by 56

Unbalanced translocation der(1;7)(q10;p10) defines a unique clinicopathological subgroup of myeloid neoplasms

Sanada, M., Uike, N., Ohyashiki, K., OZAWA, K., Li-li, W., Hangaishi, A., Kanda, Y., Chiba, S., Kurokawa, M., Omine, M., et al. (2007) · Leukemia · doi:10.1038/sj.leu.2404619 · Cited by 53

Effectiveness and safety of different azacitidine dosage regimens in patients with myelodysplastic syndromes or acute myeloid leukemia

García‐Delgado, R., de Miguel, D., Bailén, A., Gonzalez, J. R., Bargay, J., Falantes, J. F., Andreu, R., Ramos, F., Tormo, M., Brunet, S., et al. (2014) · Leukemia Research · doi:10.1016/j.leukres.2014.03.004 · Cited by 53

Treatment of higher risk myelodysplastic syndrome patients unresponsive to hypomethylating agents with ON 01910.Na

Seetharam, M., Fan, A. C., Tran, M., Xu, L., Renschler, J. P., Felsher, D. W., Sridhar, K. J., Wilhelm, F. E., & Greenberg, P. L. (2011) · Leukemia Research · doi:10.1016/j.leukres.2011.08.022 · Cited by 53

Allogeneic haematopoietic SCT for chronic myelomonocytic leukaemia: a single-centre experience

Krishnamurthy, P., Lim, Z. Y., Nagi, W., Kenyon, M., Mijovic, A., Ireland, R. M., Marsh, J. C. W., Ho, A. Y. L., Mufti, G. J., & Pagliuca, A. (2010) · Bone Marrow Transplantation · doi:10.1038/bmt.2009.375 · Cited by 53

Elevated MLF1 expression correlates with malignant progression from myelodysplastic syndrome

Matsumoto, N., Yoneda‐Kato, N., Iguchi, T., Kishimoto, Y., Kyo, T., Sawada, H., Tatsumi, E., & Fukuhara, S. (2000) · Leukemia · doi:10.1038/sj.leu.2401897 · Cited by 53

Upfront Allogeneic Stem Cell Transplantation after Reduced-Intensity/Nonmyeloablative Conditioning for Patients with Myelodysplastic Syndrome: A Study by the Société Française de Greffe de Moelle et de Thérapie Cellulaire

Damaj, G. L., Mohty, M., Robin, M., Michallet, M., Chevallier, P., Beguin, Y. P., Nguyen, S., Bories, P., Blaise, D., Maillard, N., et al. (2014) · Transplantation and Cellular Therapy · doi:10.1016/j.bbmt.2014.05.010 · Cited by 54

Evaluation of dysplastic features in myelodysplastic syndromes: experience from the morphology group of the European Working Group of MDS in Childhood (EWOG-MDS)

for the European Working Group on Myelodysplastic Syndromes in Childhood (EWOG-MDS), Rajnoldi, A. C., Fenu, S., Kerndrup, G. B., van Wering, E. R., Niemeyer, C. M., & Baumann, I. (2005) · Annals of Hematology · doi:10.1007/s00277-005-1034-4 · Cited by 53

Prognostic Importance of Histone MethyltransferaseMLL5Expression in Acute Myeloid Leukemia

Damm, F., Oberacker, T., Thol, F. R., Surdziel, E., Wagner, K., Chaturvedi, A., Morgan, M. A., Bomm, K., Göhring, G., Lübbert, M., et al. (2011) · Journal of Clinical Oncology · doi:10.1200/jco.2010.31.1118 · Cited by 55

Iron overload in myelodysplastic syndromes: A Canadian consensus guideline

Wells, R. A., Leber, B. F., Buckstein, R. J., Lipton, J. H., Hasegawa, W. S., Grewal, K. S., Yee, K. W. L., Olney, H. J., Larratt, L. M., Vickars, L. M., et al. (2008) · Leukemia Research · doi:10.1016/j.leukres.2008.02.021 · Cited by 55

Poor Outcome of Patients With Myelodysplastic Syndrome After Azacitidine Treatment Failure

Duong, V. H., Lin, K., Reljic, T., Kumar, A., Ali, N. H. A., Lancet, J. E., List, A. F., & Komrokji, R. S. (2013) · Clinical Lymphoma Myeloma & Leukemia · doi:10.1016/j.clml.2013.07.007 · Cited by 53

A prospective multicenter observational study of decitabine treatment in Korean patients with myelodysplastic syndrome

Lee, J., Jang, J. H., Park, J., Park, S. H., Joo, Y., Kim, Y.-K., Kim, H.-G., Choi, C. W., Kim, S. H., Park, S. K., et al. (2011) · Haematologica · doi:10.3324/haematol.2011.046078 · Cited by 53

Myelodysplastic/Myeloproliferative Neoplasms

Cazzola, M., Malcovati, L., & Invernizzi, R. (2011) · Hematology · doi:10.1182/asheducation-2011.1.264 · Cited by 55

Treatment of low-risk myelodysplastic syndromes

Santini, V. (2016) · Hematology · doi:10.1182/asheducation-2016.1.462 · Cited by 53

Negative Effect of DNA Hypermethylation on the Outcome of Intensive Chemotherapy in Older Patients with High-Risk Myelodysplastic Syndromes and Acute Myeloid Leukemia following Myelodysplastic Syndrome

Grövdal, M., Khan, R., Aggerholm, A., Antunović, P., Astermark, J., Bernell, P., Engström, L.-M., Kjeldsen, L., Linder, O., Nilsson, L., et al. (2007) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-07-1193 · Cited by 52

Anemia as the Main Manifestation of Myelodysplastic Syndromes

Santini, V. (2015) · Seminars in Hematology · doi:10.1053/j.seminhematol.2015.06.002 · Cited by 52

Better prognosis for patients with del(7q) than for patients with monosomy 7 in myelodysplastic syndrome

Córdoba, I., González‐Porras, J. R., Nomdedeu, B., Luño, E., de Paz, R., Such, E., Tormo, M., Vallespı́, T., Collado, R., Xicoy, B., et al. (2011) · Cancer · doi:10.1002/cncr.26279 · Cited by 52

Clinical Presentation, Diagnosis, and Prognosis of Myelodysplastic Syndromes

Foran, J. M., & Shammo, J. M. (2012) · The American Journal of Medicine · doi:10.1016/j.amjmed.2012.04.015 · Cited by 52

Single-Unit Cord Blood Transplantation after Granulocyte Colony-Stimulating Factor–Combined Myeloablative Conditioning for Myeloid Malignancies Not in Remission

Konuma, T., Kato, S., Ooi, J., Oiwa‐Monna, M., Ebihara, Y., Mochizuki, S., Yuji, K., Ohno, N., Kawamata, T., Jo, N., et al. (2013) · Transplantation and Cellular Therapy · doi:10.1016/j.bbmt.2013.12.555 · Cited by 52

Oral Clofarabine in the Treatment of Patients With Higher-Risk Myelodysplastic Syndrome

Faderl, S. H., Garcia‐Manero, G., Estrov, Z. E., Ravandi, F., Borthakur, G. M., Cortes, J. E., O'Brien, S. M., Gandhi, V. V., Plunkett, W. K., Byrd, A. L., et al. (2010) · Journal of Clinical Oncology · doi:10.1200/jco.2009.26.3509 · Cited by 51

Increased peripheral platelet destruction and caspase-3–independent programmed cell death of bone marrow megakaryocytes in myelodysplastic patients

Houwerzijl, E. J., Blom, N. R., van der Want, J. J. L., Louwes, H., Esselink, M. T., Smit, J. W., Vellenga, E., & de Wolf, J. T. M. (2004) · Blood · doi:10.1182/blood-2004-06-2108 · Cited by 52

Prophylactic RhCE and Kell antigen matching: impact on alloimmunization in transfusion‐dependent patients with myelodysplastic syndromes

Lin, Y., Saskin, A., Wells, R. A., Lenis, M., Mamedov, A., Callum, J., & Buckstein, R. J. (2016) · Vox Sanguinis · doi:10.1111/vox.12455 · Cited by 52

Myelodysplastic Syndromes

Orazi, A., & Czader, M. (2009) · American Journal of Clinical Pathology · doi:10.1309/ajcprcxx4r0yhkwv · Cited by 53

Marrow Fibrosis as a Risk Factor for Posttransplantation Outcome in Patients with Advanced Myelodysplastic Syndrome or Acute Myeloid Leukemia with Multilineage Dysplasia

Scott, B. L., Storer, B. E., Greene, J. E., Hackman, R. C., Appelbaum, F. R., & Deeg, H. J. (2007) · Transplantation and Cellular Therapy · doi:10.1016/j.bbmt.2006.10.030 · Cited by 52

The paradox of 20q11.21 amplification in a subset of cases of myeloid malignancy with chromosome 20 deletion

MacKinnon, R. N., Selan, C., Wall, M., Baker, E. G., Nandurkar, H. H., & Campbell, L. J. (2010) · Genes Chromosomes and Cancer · doi:10.1002/gcc.20806 · Cited by 52

Does isochromosome 7q mandate bone marrow transplant in children with Shwachman–Diamond syndrome?

Cunningham, J., Sales, M., Pearce, A., Howard‐Reeves, J., Stallings, R. L., Telford, N., Wilkie, R., Huntly, B. J. P., Thomas, A. E., O'Marcaigh, A. S., et al. (2002) · British Journal of Haematology · doi:10.1046/j.1365-2141.2002.03940.x · Cited by 52

Low‐dose melphalan induces favourable responses in elderly patients with high‐risk myelodysplastic syndromes or secondary acute myeloid leukaemia

Denzlinger, Bowen, Benz, Gelly, Brugger, & Kanz (2000) · British Journal of Haematology · doi:10.1046/j.1365-2141.2000.01825.x · Cited by 52

Iron overload-induced oxidative stress in myelodysplastic syndromes and its cellular sequelae

Kim, C. H., & Leitch, H. A. (2021) · Critical Reviews in Oncology/Hematology · doi:10.1016/j.critrevonc.2021.103367 · Cited by 54

Azacitidine

Keating, G. M. (2012) · Drugs · doi:10.2165/11209430-000000000-00000 · Cited by 51

Prospective assessment of effects on iron-overload parameters of deferasirox therapy in patients with myelodysplastic syndromes

Greenberg, P. L., Koller, C. A., Cabantchik, Z. I., Warsi, G. M., Glynos, T., Paley, C. S., & Schiffer, C. A. (2010) · Leukemia Research · doi:10.1016/j.leukres.2010.06.013 · Cited by 51

Monosomal karyotype predicts poor survival after allogeneic stem cell transplantation in chromosome 7 abnormal myelodysplastic syndrome and secondary acute myeloid leukemia

van Gelder, M., de Wreede, L. C., Schetelig, J., van Biezen, A., Volin, L., Maertens, J. A., Robin, M., Petersen, E. J., de Witte, T., Kröger, N. M., et al. (2012) · Leukemia · doi:10.1038/leu.2012.297 · Cited by 51

Chronic neutrophilic leukemia and chronic myelomonocytic leukemia: WHO defined

Elliott, M. A. (2006) · Best Practice & Research Clinical Haematology · doi:10.1016/j.beha.2005.07.012 · Cited by 51

Serum iron metabolism and erythropoiesis in patients with myelodysplastic syndrome not receiving RBC transfusions

Cui, R., Gale, R. P., Zhu, G., Xu, Z., Qin, T., Zhang, Y., Huang, G., Li, B., Fang, L., Zhang, H., et al. (2014) · Leukemia Research · doi:10.1016/j.leukres.2014.01.016 · Cited by 52

Clinical effect of increasing doses of lenalidomide in high-risk myelodysplastic syndrome and acute myeloid leukemia with chromosome 5 abnormalities

Möllgård, L., Saft, L., Treppendahl, M. B., Dybedal, I., Nørgaard, J. M., Astermark, J., Ejerblad, E., Garelius, H. G., Dufva, I. H., Jansson, M., et al. (2011) · Haematologica · doi:10.3324/haematol.2010.039669 · Cited by 51

Myelodysplastic Syndromes Classification and Risk Stratification

Komrokji, R. S., Zhang, L., & Bennett, J. M. (2010) · Hematology/Oncology Clinics of North America · doi:10.1016/j.hoc.2010.02.004 · Cited by 51

Diagnostic value of histology and immunohistochemistry in myelodysplastic syndromes

Horny, H., Sotlar, K., & Valent, P. (2007) · Leukemia Research · doi:10.1016/j.leukres.2007.05.010 · Cited by 51

Higher fetuin-A, lower adiponectin and free leptin levels mediate effects of excess body weight on insulin resistance and risk for myelodysplastic syndrome

Dalamaga, Μ., Καρμανιώλας, Κ., Chamberland, J. P., Nikolaidou, A., Lekka, A., Dionyssiou‐Asteriou, A., & Mantzoros, C. S. (2013) · Metabolism · doi:10.1016/j.metabol.2013.09.007 · Cited by 51

Myelodysplastic Syndromes and Acute Myeloid Leukemia in the Elderly

Klepin, H. D. (2015) · Clinics in Geriatric Medicine · doi:10.1016/j.cger.2015.08.010 · Cited by 53

Lenalidomide use in myelodysplastic syndromes: Insights into the biologic mechanisms and clinical applications

Stahl, M. F., & Zeidan, A. M. (2017) · Cancer · doi:10.1002/cncr.30585 · Cited by 52

Exploration of the role of gene mutations in myelodysplastic syndromes through a sequencing design involving a small number of target genes

Xu, F., Wu, L., He, Q., Wu, D., Zhang, Z., Song, L., Zhao, Y., Su, J., Zhou, L.-Y., Guo, J., et al. (2017) · Scientific Reports · doi:10.1038/srep43113 · Cited by 52

Current status and trends in the diagnostics of AML and MDS

Shumilov, E., Flach, J., Kohlmann, A., Banz, Y., Bonadies, N., Fiedler, M., Pabst, T., & Bacher, U. (2018) · Blood Reviews · doi:10.1016/j.blre.2018.04.008 · Cited by 52

A phase II study of guadecitabine in higher-risk myelodysplastic syndrome and low blast count acute myeloid leukemia after azacitidine failure

Sébert, M., Renneville, A., Bally, C., Péterlin, P., Beyne‐Rauzy, O., Legros, L., Gourin, M.-P., Sanhès, L., Wattel, E., Gyan, E., et al. (2019) · Haematologica · doi:10.3324/haematol.2018.207118 · Cited by 51

Centromeric breakage and highly rearranged chromosome derivatives associated with mutations of TP53 are common in therapy‐related MDS and AML after therapy with alkylating agents: An M‐FISH study

Andersen, M. K., Christiansen, D. H., & Pedersen-Bjergaard, J. (2005) · Genes Chromosomes and Cancer · doi:10.1002/gcc.20145 · Cited by 51

Is International Prognostic Scoring System (IPSS) still standard in predicting prognosis in patients with myelodysplastic syndrome? External validation of the WHO Classification‐Based Prognostic Scoring System (WPSS) and comparison with IPSS

Park, M. J., Kim, H., Kim, S., Kim, D. H., Kim, S. J., Jang, J. H., Kım, K., Kim, W. S., & Jung, C. W. (2008) · European Journal Of Haematology · doi:10.1111/j.1600-0609.2008.01124.x · Cited by 51

Myelodysplastic syndrome: review of the cytogenetic and molecular data

Mhawech, P., & Saleem, A. (2001) · Critical Reviews in Oncology/Hematology · doi:10.1016/s1040-8428(01)00101-9 · Cited by 51

A Practical, Comprehensive Classification for Pediatric Myelodysplastic Syndromes: The CCC System

Mandel, K. M., Dror, Y., Poon, A., & Freedman, M. H. (2002) · Journal of Pediatric Hematology/Oncology · doi:10.1097/00043426-200206000-00005 · Cited by 51

Activity of the caspase-3/CPP32 enzyme is increased in “early stage” myelodysplastic syndromes with excessive apoptosis, but caspase inhibition does not enhance colony formation in vitro

Bouscary, D., Chen, Y. L., Guesnu, M., Picard, F., Viguier, F., Lacombe, C., Dreyfus, F., & Fontenay, M. (2000) · Experimental Hematology · doi:10.1016/s0301-472x(00)00179-x · Cited by 51

Cytopenia levels for aiding establishment of the diagnosis of myelodysplastic syndromes

Greenberg, P. L., Tuechler, H., Schanz, J., Sanz, G. F., Garcia‐Manero, G., Solé, F. G., Bennett, J. M., Bowen, D., Fenaux, P., Dreyfus, F., et al. (2016) · Blood · doi:10.1182/blood-2016-07-728766 · Cited by 51

Myelodysplastic syndromes: 2011 update on diagnosis, risk‐stratification, and management

Garcia‐Manero, G. (2011) · American Journal of Hematology · doi:10.1002/ajh.22047 · Cited by 50

Clinical Implications of the SETBP1 Mutation in Patients With Primary Myelodysplastic Syndrome and its Stability During Disease Progression

Hou, H., Kuo, Y. Y., Tang, J., Chou, W. W., Yao, M., Lai, Y., Lin, C., Chen, C., Liu, C. Y., Lee, M. C., et al. (2014) · Clinical Lymphoma Myeloma & Leukemia · doi:10.1016/j.clml.2014.06.095 · Cited by 50

Eltrombopag monotherapy can improve hematopoiesis in patients with low to intermediate risk-1 myelodysplastic syndrome

Vicente, A., Patel, B. A., Gutierrez‐Rodrigues, F., Groarke, E. M., Giudice, V., Lotter, J., Feng, X., Kajigaya, S., Weinstein, B., Barranta, M. E., et al. (2020) · Haematologica · doi:10.3324/haematol.2020.249995 · Cited by 50

−7/7q− syndrome in myeloid-lineage hematopoietic malignancies: attempts to understand this complex disease entity

Honda, H., Nagamachi, A., & Inaba, T. (2014) · Oncogene · doi:10.1038/onc.2014.196 · Cited by 50

Erythroid precursors from patients with low-risk myelodysplasia demonstrate ultrastructural features of enhanced autophagy of mitochondria

Houwerzijl, E. J., Pol, H.-W., Blom, N. R., van der Want, J. J. L., de Wolf, J., & Vellenga, E. (2009) · Leukemia · doi:10.1038/leu.2008.389 · Cited by 52

Risk factors and their relationship to prognosis in myelodysplastic syndromes

Greenberg, P. L. (1998) · Leukemia Research · doi:10.1016/s0145-2126(98)00040-x · Cited by 19

Clinical Prognostic Factors for Survival and Risk of Progression to Acute Myeloid Leukemia in Patients With Myelodysplastic Syndromes With < 10% Marrow Blasts and Non-Unfavorable Cytogenetic Categories

Falantes, J. F., Calderón, C., Márquez-Malaver, F. J., Alonso, D., Noya, A. M., Carrillo, E., Martino, M. L., Montero, I., González, J., Parody, R., et al. (2012) · Clinical Lymphoma Myeloma & Leukemia · doi:10.1016/j.clml.2012.09.013 · Cited by 19

New Comprehensive Cytogenetic Scoring System for Primary Myelodysplastic Syndromes (MDS) and Oligoblastic Acute Myeloid Leukemia After MDS Derived From an International Database Merge

Schanz, J., Tüchler, H., Solé, F. G., Mallo, M., Luño, E., Cervera, J., Granada, I., Hildebrandt, B., Slovak, M. L., Ohyashiki, K., et al. (2012) · Journal of Clinical Oncology · doi:10.1200/jco.2011.35.6394 · Cited by 688

Growing Evidence for an Underestimation of Poor-Risk Cytogenetics in the International Prognostic Scoring System in Myelodysplastic Syndromes

Steidl, C., Schanz, J., Pfeilstöcker, M., Nösslinger, T., Hildebrandt, B., Kuendgen, A., Lübbert, M., Kunzmann, R., Giagounidis, A. A. N., Aul, C., et al. (2007) · Clinical Leukemia · doi:10.3816/clk.2007.n.029 · Cited by 8

Coalesced Multicentric Analysis of 2,351 Patients With Myelodysplastic Syndromes Indicates an Underestimation of Poor-Risk Cytogenetics of Myelodysplastic Syndromes in the International Prognostic Scoring System

Schanz, J., Steidl, C., Fonatsch, C., Pfeilstöcker, M., Nösslinger, T., Tuechler, H., Valent, P., Hildebrandt, B., Giagounidis, A. A. N., Aul, C., et al. (2011) · Journal of Clinical Oncology · doi:10.1200/jco.2010.28.3978 · Cited by 159